About
This medication is a fixed-dose combination of Vildagliptin and Metformin, indicated for the treatment of type 2 diabetes mellitus. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's natural ability to control blood glucose by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily works by reducing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. The synergistic action of these two agents provides comprehensive glycemic control, addressing multiple pathophysiological defects in type 2 diabetes.
This combination therapy is typically used when diet and exercise, along with either Vildagliptin or Metformin alone, do not provide adequate glycemic control. It offers a convenient and effective approach to managing blood sugar levels, reducing HbA1c, and improving overall metabolic health in adults with type 2 diabetes, often leading to better patient adherence due to fewer pills.
Uses
- Management of type 2 diabetes mellitus in adults.
- Improvement of glycemic control as an adjunct to diet and exercise.
- Used when monotherapy with Vildagliptin or Metformin is insufficient.
- Combination therapy with other antidiabetic agents when needed.
Directions For Use
Take orally with meals, usually once or twice daily, as directed by your physician to minimize gastrointestinal side effects.
Benefits
- Significant reduction in HbA1c levels.
- Synergistic action for comprehensive glycemic control.
- Lower risk of hypoglycemia compared to sulfonylureas.
- Potential for weight stabilization or modest weight loss (due to Metformin).
- Improved insulin sensitivity and reduced hepatic glucose production.
- Convenient fixed-dose combination, potentially improving adherence.
Side Effects
- Nausea
- Diarrhea
- Abdominal pain
- Headache
- Dizziness
- Nasopharyngitis
- Cough
- Tremor
- Fatigue
- Hypoglycemia (rare)
- Lactic acidosis (Metformin, rare but serious)
- Pancreatitis (Vildagliptin, very rare)
Safety Measures
- Alcohol - Avoid excessive alcohol consumption due to an increased risk of lactic acidosis, a rare but serious side effect of Metformin.
- Pregnancy - Generally not recommended during pregnancy; consult your doctor to discuss safer alternatives for glycemic control.
- Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk; consult your doctor.
- Liver - Use with caution in patients with liver impairment; Metformin is contraindicated in severe hepatic impairment due to lactic acidosis risk.
- Kidney - Dose adjustment is crucial in renal impairment; Metformin is contraindicated in severe renal impairment due to lactic acidosis risk.
- Lung - Use with caution in severe respiratory conditions or hypoxia, as these can increase the risk of lactic acidosis with Metformin.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!